Gelie Meiniao (格列美脲)格列美脲
This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。
Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。
生产企业Manufacturer
- 山东新华制药股份有限公司Chinese legal name: 山东新华制药股份有限公司
主要成分Active Ingredients
- 格列美脲Gelie Meiniao
药物知识说明
格列美脲是一种在国家药监局注册认定的药品。该药品含有格列美脲-4a0733c8等成分。
该药品关联的活性成分包括：格列美脲Gelie Meiniao。这些成分信息来自国家药监局数据库。
该药品标注的生产企业为：山东新华制药股份有限公司Chinese legal name: 山东新华制药股份有限公司。
您可以探索含有相同成分的其他药品：格列美脲-4a0733c8成分药品。
本页面内容来自国家药监局数据库，MedicineGraph在此基础上提供关系图谱和知识导航。
Medicine Knowledge
This medicine (original name: 格列美脲) is a medicine registered with the national drug regulatory authority. It contains recorded ingredients as active ingredient(s).
Active ingredients associated with this product: 格列美脲Gelie Meiniao.
Manufacturers recorded for this product: 山东新华制药股份有限公司Chinese legal name: 山东新华制药股份有限公司.
Explore other medicines containing the same ingredient: 格列美脲 productsProducts containing this recorded ingredient.
Source: MedicineGraph authoritative database. Relationships derived from registered product information.
这是什么What is this
- 通用名/品名Recorded product name: 格列美脲Recorded Chinese name: 格列美脲
- 规格Specification: ----
本段仅展示注册/说明书已记录的身份属性，不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.
主要成分Ingredients
生产企业Manufacturer
- 山东新华制药股份有限公司Chinese legal name: 山东新华制药股份有限公司
注册信息NMPA approval number
- 批准文号NMPA approval number: 国药准字H20010570
关联实体Relationships
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.
- 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
- 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.
本段为已核准说明书原文摘录（非改写、非AI摘要），非正式英文标签，亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.
English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.
NMPA approval number
国药准字H20010570
Manufacturer
Chinese legal name: 山东新华制药股份有限公司 (domestically manufactured)
Indications
English translation unavailable. The original Chinese source label remains available below.
Dosage and administration
English translation unavailable. The original Chinese source label remains available below.
Adverse reactions
English translation unavailable. The original Chinese source label remains available below.
Contraindications
English translation unavailable. The original Chinese source label remains available below.
Precautions
English translation unavailable. The original Chinese source label remains available below.
Storage
Protect from light and keep tightly closed.
Specification
English translation unavailable. The original Chinese source label remains available below.
中文说明书原文Original Chinese source label
批准文号
国药准字H20010570
生产企业
山东新华制药股份有限公司(国产)
适应症
适用于控制饮食、运动疗法及减轻体重均不能充分控制血糖的2型糖尿病。
用法用量
口服，遵医嘱用。
不良反应
1.低血糖，本品可引起低血糖症，尤其老年体弱患者在治疗初期，不规则进食，饮酒及肝肾功能损害患者，据报道，发生率为2%。
2.消化系统症状：恶心呕吐，腹泻、腹痛少见。
3.有个别病例报道血清肝脏转氨酶升高。
4.皮肤过敏反应，瘙痒、红斑、荨麻疹少见。
5.其他：头痛、乏力、头晕少见。
禁忌
1.已知对格列美脲有过敏史者禁用。
2.糖尿病酮症酸中毒伴或不伴昏迷者禁用，这种情况应用胰岛素治疗。
3.孕妇、分娩妇女、哺乳期妇女禁用。
注意事项
1.病人用药时应遵医嘱，注意饮食，运动和用药时间。
2.治疗中应注意早期出现的低血糖症状，如头痛、兴奋、失眠、震颤和大量出汗，以便及时采取措施，严重者应静脉滴注葡萄糖液，对有创伤、术后，感染或发热病人应给与胰岛素维持正常血糖代谢。
3.避免饮酒，以免引起类戒断反应。
贮藏
遮光，密封保存。
规格
----
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据。National Medical Products Administration (China) medicine-registration data.
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.